What Your Bloodwork Should Show at Month 6: A Men's Lab Panel Guide

By month 6 on a GLP-1, your body has been through a metabolic overhaul. Your bloodwork should reflect it — and knowing what to look for, what's normal, and what warrants a call to your doctor turns a routine lab panel into a roadmap of your transformation.

Most men on GLP-1 medications get bloodwork done at the start of treatment and then forget about it until their provider orders follow-up labs a year later. That's a missed opportunity. Month 6 is the ideal inflection point — enough time for medication and weight loss to produce measurable metabolic changes, early enough to catch and correct anything that's trending the wrong direction.

THE ESSENTIAL PANEL

Here's what your month-6 lab panel should include, what each marker tells you, and what the numbers should look like if your GLP-1 treatment is working:

METABOLIC MARKERS

A1C (Hemoglobin A1C)

• What it measures: Average blood sugar over the past 3 months
• Target: Below 5.7% (normal). If you started in the prediabetic range (5.7–6.4%), you should see meaningful improvement by month 6
• Expected change: 0.5–1.5 point reduction from baseline, depending on starting level and weight lost
• Concern if: A1C hasn't budged or has increased despite weight loss — could indicate an underlying pancreatic issue or medication non-response

Fasting Glucose

• What it measures: Blood sugar after an overnight fast — a real-time snapshot vs. A1C's 3-month average
• Target: Below 100 mg/dL
• Expected change: 10–30 mg/dL reduction from baseline

Fasting Insulin

• What it measures: How hard your pancreas is working to control blood sugar. High fasting insulin = insulin resistance
• Target: Below 10 μIU/mL (optimal: 3–5)
• Expected change: 30–50% reduction from baseline. This is one of the most dramatic lab improvements GLP-1 medications produce

LIPID PANEL

Triglycerides

• Target: Below 150 mg/dL (optimal: below 100)
• Expected change: 15–30% reduction. Triglycerides respond aggressively to visceral fat loss — often the most improved lipid marker at month 6

HDL Cholesterol

• Target: Above 40 mg/dL (optimal: above 50)
• Expected change: 5–15% increase. HDL improves slowly but steadily with weight loss and increased physical activity

LDL Cholesterol

• Target: Below 100 mg/dL (lower for men with cardiovascular disease history)
• Expected change: Variable. LDL may not change significantly with GLP-1 treatment alone — statins remain the primary intervention for elevated LDL

Triglyceride-to-HDL Ratio

• Target: Below 2.0 (optimal: below 1.5)
• Why it matters: This ratio is a stronger predictor of cardiovascular risk than any individual lipid number. A man with triglycerides of 120 and HDL of 55 (ratio: 2.2) has meaningfully different risk than a man with triglycerides of 80 and HDL of 60 (ratio: 1.3)

LIVER FUNCTION

ALT and AST

• Target: ALT below 40 U/L, AST below 40 U/L
• Expected change: Significant reduction in men who had elevated baseline levels (common with fatty liver disease). GLP-1 medications produce some of the most dramatic liver enzyme improvements of any intervention — reductions of 30–60% are not unusual
• Concern if: Enzymes are increasing rather than decreasing — warrants further liver evaluation

KIDNEY FUNCTION

Creatinine and eGFR

• Target: Creatinine in normal range (0.7–1.3 mg/dL), eGFR above 60
• Why it's here: GLP-1 medications are kidney-protective (the FLOW trial showed 24% reduction in kidney disease progression), but monitoring ensures no unexpected kidney impact from dehydration or other factors

THYROID FUNCTION

TSH

• Target: 0.4–4.0 mIU/L
• Why it's here: GLP-1 receptor agonists carry a theoretical thyroid risk based on rodent studies (medullary thyroid carcinoma). While this has not been observed in humans at meaningful rates, annual TSH monitoring provides reassurance and catches incidental thyroid disorders

TESTOSTERONE (FOR MEN WITH BASELINE LOW-T)

Total Testosterone

• Target: Above 300 ng/dL (optimal: 400–700 for most men)
• Expected change: 15–30% increase from baseline in overweight men, driven by reduced aromatization and improved SHBG levels. The ENDO 2025 data showed testosterone normalization (53% → 77% in normal range) after significant weight loss

Free Testosterone

• Why both: Total testosterone can increase while free testosterone (the biologically active fraction) lags due to SHBG changes. Testing both provides the complete picture

INFLAMMATORY MARKERS

High-Sensitivity CRP (hs-CRP)

• Target: Below 1.0 mg/L (low cardiovascular risk)
• Expected change: 30–50% reduction. CRP is one of the most responsive markers to GLP-1 treatment, often dropping before significant weight loss occurs (evidence of the medication's direct anti-inflammatory effect)

READING YOUR RESULTS

Don't compare your month-6 numbers to population reference ranges. Compare them to your baseline. A man whose A1C went from 6.2 to 5.5 has achieved something clinically significant — even though 5.5 is within "normal" and doesn't look dramatic in isolation. The trajectory matters more than the snapshot.

Similarly, a triglyceride level of 135 at month 6 isn't concerning in isolation — but if it was 90 at baseline and you've been losing weight, the upward trend warrants investigation (possible dietary change, alcohol intake increase, or thyroid issue).

THE BOTTOM LINE

Month 6 labs are your treatment report card. They confirm what's working, flag what needs attention, and provide the data your provider needs to optimize your protocol going forward. The 20 minutes in the lab and the $100–$300 for the panel (often covered by insurance) is the highest-ROI health investment you'll make during your GLP-1 treatment.